AxoGen (NASDAQ:AXGN) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of AxoGen (NASDAQ:AXGN – Get Rating) in a research note issued to investors on Thursday. The firm set a “buy” rating on the medical equipment provider’s stock.

Separately, JMP Securities reissued a “market outperform” rating and issued a $20.00 price target on shares of AxoGen in a research report on Wednesday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, AxoGen presently has an average rating of “Buy” and an average price target of $17.00.

AxoGen Stock Performance

AxoGen stock opened at $8.22 on Thursday. The stock’s 50 day simple moving average is $9.16 and its two-hundred day simple moving average is $10.32. The company has a debt-to-equity ratio of 0.65, a quick ratio of 3.54 and a current ratio of 4.35. The stock has a market cap of $350.19 million, a price-to-earnings ratio of -12.09 and a beta of 0.54. AxoGen has a fifty-two week low of $6.87 and a fifty-two week high of $13.66.

Insider Transactions at AxoGen

In other news, CFO Peter J. Mariani sold 14,320 shares of the business’s stock in a transaction that occurred on Tuesday, January 31st. The stock was sold at an average price of $9.55, for a total value of $136,756.00. Following the sale, the chief financial officer now directly owns 55,555 shares of the company’s stock, valued at approximately $530,550.25. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CFO Peter J. Mariani sold 20,939 shares of the business’s stock in a transaction that occurred on Thursday, January 26th. The shares were sold at an average price of $9.90, for a total value of $207,296.10. Following the completion of the transaction, the chief financial officer now directly owns 42,108 shares in the company, valued at approximately $416,869.20. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Peter J. Mariani sold 14,320 shares of the business’s stock in a transaction that occurred on Tuesday, January 31st. The stock was sold at an average price of $9.55, for a total transaction of $136,756.00. Following the completion of the transaction, the chief financial officer now owns 55,555 shares of the company’s stock, valued at $530,550.25. The disclosure for this sale can be found here. Insiders own 7.51% of the company’s stock.

Hedge Funds Weigh In On AxoGen

A number of hedge funds have recently added to or reduced their stakes in AXGN. HighMark Wealth Management LLC raised its holdings in AxoGen by 851.1% in the 3rd quarter. HighMark Wealth Management LLC now owns 2,235 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 2,000 shares during the last quarter. Almanack Investment Partners LLC. purchased a new stake in AxoGen during the 3rd quarter valued at $27,000. Lazard Asset Management LLC raised its stake in AxoGen by 1,282.6% during the 1st quarter. Lazard Asset Management LLC now owns 5,088 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 4,720 shares during the last quarter. Royal Bank of Canada raised its stake in AxoGen by 610.2% during the 3rd quarter. Royal Bank of Canada now owns 6,129 shares of the medical equipment provider’s stock valued at $74,000 after buying an additional 5,266 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in AxoGen by 139.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 8,909 shares of the medical equipment provider’s stock valued at $106,000 after buying an additional 5,184 shares during the last quarter. 76.22% of the stock is currently owned by hedge funds and other institutional investors.

About AxoGen

(Get Rating)

Axogen, Inc engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm’s products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator.